Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if EDIT is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
34 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 40 days ago
Red flags: 0
214 filers reported a long position in EDIT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| TCG Crossover Management, LLC | $36M | 11.1M | New |
| BlackRock, Inc. | $34.3M | 10.6M | +14.3% |
| RA CAPITAL MANAGEMENT, L.P. | $28.8M | 8.9M | New |
| Commodore Capital LP | $28.8M | 8.9M | New |
| ADAR1 Capital Management, LLC | $28.8M | 8.9M | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.9M | 6.1M | +46.1% |
| Paradigm Biocapital Advisors LP | $18.1M | 5.6M | New |
| Opaleye Management Inc. | $12.5M | 3.9M | +100.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.7M | 3.6M | +14.3% |
| Woodline Partners LP | $11.5M | 3.6M | New |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.